Clinical Trial Update: A Study of LY3435151 in Participants With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of LY3435151 in solid tumors, including triple-negative breast cancer, terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Carcinoma
• Gastric Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• High-grade Serous Ovarian Carcinoma
• Leiomyosarcoma
• Solid Tumor
• Triple-negative Breast Cancer
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• LY3435151 (LY3435151)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Solid Tumor, Triple-negative Breast Cancer | Phase 1 | Status: TERMINATED | Results posted: 2021-08-31